HMC- Department of Laboratory Medicine and Pathology earns CAP re-accreditation

Hamad Medical Corporation’s (HMC) Department of Laboratory Medicine and Pathology (DLMP) has been reaccredited by the College of American Pathologists (CAP) for the sixth consecutive cycle with high commendation by a highly experienced international team of inspectors from North America.
Additionally, Aisha Bint Hamad Al Attiyah Hospital, opened in 2022, underwent inspection for the first time and received CAP accreditation with zero deficiencies. The CAP inspections took place from February 18 to 25 this year and are held every two years.
The DLMP not only serves the patients of HMC but also provides referral services to more than 140 customers across Qatar including government, semi-government and private sectors. The department performs more than 21mn tests per year, including tests for the Blood Bank Service, and provides a comprehensive range of specialised laboratory services for the people of Qatar.
Dr Einas al-Kuwari, chairperson, DLMP said: “CAP Accreditation demonstrates HMC’s high-standard quality assurance and quality control programs and is a major milestone for the Corporation and Qatar. The designation places HMC’s laboratories among an elite class of organizations globally and demonstrates the importance we place on delivering the safest, highest quality and most effective patient care.
“It is the invaluable contribution of our laboratory pathologists, consultants, clinical scientists, supervisors, technical and support staff along with the quality, safety and administration teams that enable us to achieve this prestigious re-accreditation.”
The CAP Accreditation is founded on the most exacting standards in clinical diagnostic laboratories and is designed to provide assurance to the public and patients that the laboratory services are safe and that the public can have full confidence in the results and interpretative advice provided.
According to Dr al-Kuwari the DLMP is working on expanding services to offer as well as being at the forefront of new and innovative treatments.
“Precision medicine, regenerative medicine, artificial intelligence and molecular diagnostics are all changing the face of healthcare and how we care for patients,” Dr al-Kuwari said. “We are ready and already working to be an integral part of the changing healthcare landscape and serve the changing needs of the patient to the highest standards.”
The DLMP has also achieved accreditation from the Association for the Advancement of Blood and Biotherapy.